Results 181 to 190 of about 308,418 (340)
A phase II trial of paclitaxel in refractory germ cell tumors
, 1998 Alan B. Sandler +6 more
openalex +1 more source
Annals of Gastroenterological Surgery, EarlyView.ABSTRACT Background Chemotherapeutic advances have increased opportunities for conversion surgery (CS) in unresectable locally advanced (UR‐LA) pancreatic cancer (PC). However, the optimal indications for CS remain unclear. Sarcopenia has been associated with poor outcomes in PC, except UR‐LA PC. Herein, we aimed to evaluate the impact of sarcopenia on
Sho Uemura +8 more
wiley +1 more source
Paclitaxel (Taxol) and Docetaxel (Taxotere): active chemotherapeutic agents in lung cancer
, 1995 Prudence A. Francis +4 more
openalex +1 more source
Annals of Gastroenterological Surgery, EarlyView.We aimed to refine treatment strategies for resected cases of pancreatic ductal adenocarcinoma in patients with unexpectedly uncovered postoperative noncurative factors. Cases with unexpected postoperative uncovering noncurative factors had significantly poorer prognoses than those without such factors.
Hiroto Matsui +20 more
wiley +1 more source
Annals of Gastroenterological Surgery, EarlyView.ABSTRACT Background Pancreatectomy for pancreatic ductal adenocarcinoma (PDAC) with arterial abutment is a complex, high‐risk surgery. We aimed to investigate the clinicopathological features, risk factors, and learning curve for local recurrence after pancreatectomy for PDAC with arterial abutment.
Jun Ishida +9 more
wiley +1 more source
Annals of Gastroenterological Surgery, EarlyView.We systematically reviewed conversion therapy for esophageal squamous cell carcinoma and propose a response‐based treatment strategy for cT4b and M1 disease. For cT4b, we emphasize definitive chemoradiotherapy with timed re‐evaluation and selective salvage or chemoselection to surgery; for M1, conversion is reserved for limited‐burden responders with ...
Eisuke Booka, Hiroya Takeuchi
wiley +1 more source
The Paclitaxel Biosynthesis Pathway Unlocked. [PDF]
Research (Wash D C)Martinelli L, Papon N, Courdavault V.
europepmc +1 more source
Microtubule-disrupting agents inhibit nitric oxide production in murine peritoneal macrophages stimulated with lipopolysaccharide or paclitaxel (Taxol) [PDF]
, 1996 Teruo Kirikae +3 more
openalex +1 more source
The Fast‐Growing Field of Cancer Immunotherapy Based on Aggregation‐Induced Emission
Aggregate, EarlyView.Photoimmunotherapy facilitated by AIEgens represents an emerging cancer treatment that combines high‐performance phototheranostics with immunotherapy to achieve satisfactory antitumor effectiveness, and has recently been developed at a tremendous pace and attracted global interests in the past few years.
Zhijie Lin +5 more
wiley +1 more source